BioSpace News Archive

New HCPCS Level II Code for Exoskeletons Would Be a Significant Step Towards Access to Exoskeletons for Individuals with Spinal Cord Injuries

OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced resumption of patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D).

LumaCyte, an advanced bioanalytical instrumentation company has demonstrated a significant advancement using its transformative Laser Force Cytology instrument, Radiance®.

Exosite LLC, a leading provider in the Industrial Internet of Things (IIoT) market, today announced that it has licensed use of certain software technology and solutions to West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration

Maralixibat-treated patients achieving serum bile acid control have five-year native liver survival after treatment. - Data demonstrate normalization and reductions of liver enzymes, reduced pruritus, and improved growth. - Data selected for oral presentation at the Digital International Liver Congress 2020 being held August 27-29, 2020. FOSTER CITY, Calif.--( BUSINESS WIRE )-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today reported

CohBar, Inc. a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, is hosting its Annual Shareholder Meeting and Investor Update on June 16, 2020.

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has reached a significant milestone of over 400 scientific publications now documenting the clinical benefits of Stereotaxis robotic technology

Kannalife, Inc., a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Company’s Board of Advisors.

AMERI Holdings, Inc. (NASDAQ: AMRH) (the “Company”), today announced that its proposed amalgamation partner Jay Pharma Inc. (“Jay Pharma”) received institutional review board (“IRB”) approval by Rabin Medical Center in Petah Tikva, Israel for a Phase I/II clinical trial investigating Jay Pharma’s proprietary cannabidiol

More than 600 ventilated patients have been successfully treated with a unique respiratory guard system, the AnapnoGuard, in the US, Israel and China.